Next Generation Dx Summit
Archived Content

CDX First Call Header 

Day 1  |  Day 2 

Finding or detecting cancer at an early stage can make it much more treatable. Molecular staging of cancer has the potential of being able to recognize subsets of the disease to allow for highly targeted therapies that can yield unprecedented results. Commercial tests need to be able to diagnose cancer with an exquisite sensitivity with just a few cells, to overcome the challenge of the heterogeneity of cancer. Plan to attend to learn what progress has been made towards developing assays with specific biomarkers to cancer that will create a new generation of products.

Scientific Advisory Board

Harry Glorikian, Managing Partner, Scientia Advisors

Myla Lai-Goldman, M.D., CEO, CancerGuide Diagnostics, Inc.

Jorge A. León, Ph.D., President, Leomics Consulting

 

MONDAY, AUGUST 23 

1:00-2:00 pm Short Course Registration 

2:00-5:00 Pre-Conference Short Courses* 

(SC1) ROADMAP FOR ACCELERATING COMMERCIALIZATION OF MOLECULAR DIAGNOSTICS 

(SC2) MICRO- AND NANOFLUIDICS IN DIAGNOSTICS AND LIFE SCIENCES:TECHNOLOGIES AND APPLICATIONS 


4:00 – 5:00 Main Conference Registration
 

*Separate registration required. Click here for details. 

 

TUESDAY, AUGUST 24 


7:30 am-6:00 pm Registration
 

7:30 Morning Coffee 

 

DEEP SEQUENCING OF CANCER GENOMES: Identifying Candidate Genes 

8:30 Chairperson’s Remarks 

Jorge A. León, Ph.D., President, Leomics Consulting 

8:40 Molecular Profiling - The Future of Cancer Treatment 

Hans Lehrach Hans Lehrach, Ph.D., Director, Max Planck Institute for Molecular Genetics, Berlin; Head, Department of Vertebrate Genomics 

It will soon be commercially feasible to apply deep sequencing in the clinic at the full-genome level to clinical patient samples, which makes the development of systems able to take advantage of this new flood of clinical information an urgent matter. We are therefore presenting a system we have developed that has the capacity to integrate these types of data in a “holistic” and comprehensive fashion. The “Virtual Patient” system allows us to create predictive models out of all the information available from any deep molecular characterisation technology, allowing the selection of an optimal therapy for each individual patient.


9:10 Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing
 

Rebecca Leary Rebecca Leary, Ph.D., Post Doctoral Fellow, Oncology, Ludwig Center for Cancer Genetics and Therapeutics, The Johns Hopkins Kimmel Cancer Center 

Personalized Analysis of Rearranged Ends (PARE) is a novel approach to identify tumor-specific rearrangements on a per-patient basis and create personalized biomarkers for detection of circulating tumor DNA. The PARE approach may be used to monitor tumor levels after therapy and determine cancer recurrence.



9:40 Expression Profiling of microRNAs in Ovarian Cancer Using Deep Sequencing
Chad Creighton Chad Creighton, Ph.D., Assistant Professor, Division of Biostatistics, Dan L. Duncan Cancer Center, Baylor College of MedicineBy comprehensively profiling expression of microRNAs and genes in ovarian cancer, we have identified strong candidate microRNAs and their target genes that may contribute to the pathogenesis of this disease. To date, we have found that miR-100 inhibits mTOR signaling and enhance sensitivity to rapamycin in clear cell cancer cell cultures, and that miR-31 inhibits proliferation and induces apoptosis in those serous cancer cell lines that have a dysfunctional p53 pathway.


Sponsored by
Edge 
10:10 Presentation Sponsored by EdgeBio
Omayma Al-Awar, Ph.D., Director of Sales and Marketing, EdgeBio
10:25 Coffee Break 

 

ONCOLOGY BIOMARKERS 

10:55 Chairperson’s Remarks 

Jorge A. León, Ph.D., President, Leomics Consulting 

11:00 High Throughput Cancer Diagnostic Discovery and Development in Using Somamers: Slow Off-Rate Modified Aptamers 

ADX_Steven_Williams Stephen A. Williams, M.D., Ph.D., CMO, SomaLogic, Inc. 

A clinical assay has been developed which uses SOMAmers to measure ~900 proteins simultaneously in 15ul of plasma or serum, with a CV of ~5% and a median LLOQ well below 1pg/ml. This combination of attributes is not currently matched by any other technology platform. The high-throughput assay has been used to discover protein signatures which diagnose cancer or predict recurrence in a number of different cancers. Relevant case studies will be discussed.

11:30 Combined Tissue and Blood Tests Based on a Novel Biomarker for Predicting and Real Time Monitoring of Breast Cancer Recurrence 

Ginette Serrero, Ph.D., CEO, Oncology Biomarker, A&G Pharmaceutical, Inc. 

Applying biological screen for target discovery has been a very powerful approach to identify targets in oncology that have therapeutic and diagnostic applications for drug resistant cancers. Using this approach we have discovered a novel biomarker that is over expressed and secreted by breast tumors and plays a critical role in breast tumorigenesis and acquisition to resistance to therapy. A tissue and blood tests were developed to detect this biomarker in breast biopsies as well as in serum. Training trial followed by a validation clinical study enrolling 264 patients have demonstrated and validated that tissue expression of this biomarker was a predictor of recurrence independent of tumor size, tumor grade, disease stage and lymph node status. On-going prospective clinical studies show that serum GP88 measurement can be used for real time monitoring of recurrence. These data and their impact on personalized medicine in breast cancer will be presented.

 

FUNDING OPPORTUNITIES IN CANCER DIAGNOSTICS 

12:00 pm Technology Funding Opportunities at the National Cancer Institute 

Avraham Rasooly, Ph.D., Program Director, Cancer Diagnosis Program, National Cancer Institute 

Cancer is uncontrolled growth of abnormal cells in the body. Cancer is recognized as a multistep process within the cell, involving multiple genomic alterations that manifest in multiple phases. A trend in cancer treatment is personalized medicine, the tailoring of treatment to the unique "molecular signature" of the patient’s cancer. Personalized medicine and the complexity of cancer demand new diagnostics tools to analyze such molecular signatures. The NCI’s Cancer Diagnosis Program support research and development of new diagnostics technologies for cancer.

12:30 Luncheon Presentation (Sponsorship Available) or Lunch on Your Own 

 

SERUM PROFILING 

2:00 Chairperson’s Remarks 

Myla Lai-Goldman, M.D., CEO, CancerGuide Diagnostics, Inc. 

2:10 Rapid Mass Spectrometric Metabolic Profiling of Blood Sera Detects Ovarian Cancer with High Accuracy 

John McDonald photo John McDonald, Ph.D., Professor and Director, Integrated Cancer Research Center, School of Biology, Georgia Institute of Technology 

We report the application of a new mass spectrometric procedure for the measurement of relative metabolite levels in sera combined with a customized functional Support Vector Machine (SVM)-based classification algorithm for diagnostic applications. As an initial test of the diagnostic power of our method, we examined sera from 94 women. The assay was able to distinguish between ovarian cancer and control groups with an unprecedented 99-100% accuracy (100% sensitivity; 99-100% specificity) demonstrating its potential as a clinically significant diagnostic test.


2:40 ColoVantage–A Test for Colorectal Cancer Using Methylated Septin 9 DNA in Plasma
 

ADX_KMuralidharan Kasinathan Muralidharan, Ph.D., Senior Director, Molecular Genetics, Quest Diagnostics Nichols Institute 

The good prognosis for colorectal cancer (CRC) when detected early has supported the value of CRC screening. However, compliance to CRC screening is low compared to for example prostate cancer screening, partly due to the inconvenience associated with colonoscopy and fecal sampling. The availability of a blood based test for CRC detection can potentially improve compliance. Detection of methylated Septin 9 DNA in plasma has been strongly correlated with CRC with a sensitivity of about 70% and specificity of about 90% in detecting CRC. We here report the development and validation of a test for methylated Septin 9 DNA in plasma.

3:10 Refreshment Break 

4:00 Interactive Panel: Practical Approach for Developing Predictive Diagnostics 

Myla Goldman Moderator: Myla Lai-Goldman, M.D., CEO, CancerGuide Diagnostics, Inc. 

  • How do we shorten the timeline from concept to delivery?
  • Charting the logical approach to make development more efficient
  • Avoiding prospective, randomized clinical trials

Panelists: 

Stephen Little, Ph.D., Vice President, Personalized Healthcare, QIAGEN (Formerly CEO, DxS Ltd.) 

Felix W. Frueh, Ph.D., Vice President, Research & Development & Personalized Medicine, Medco Health Solutions, Inc. 


Questions will be collected via email beforehand from the audience.

5:00 Opening Reception in the Exhibit Hall 

6:00 Close of Day 

 

Day 1  |  Day 2